公开(公告)号：US12060418B2

公开(公告)日：2024-08-13

申请号：US16389356

申请日：2019-04-19

Applicant: Merus N.V.

Inventor： Alexander Berthold Hendrik Bakker ,  Pieter Fokko Van Loo ,  Ton Logtenberg

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/30

CPC classification number: C07K16/28 ,  C07K16/2809 ,  C07K16/2851 ,  C07K16/3061 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/569 ,  C07K2317/70 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/92

Abstract: Bispecific IgG antibodies which bind to CLEC12A and an antigen on an immune effector cell are provided.

公开(公告)号：US20240247054A1

公开(公告)日：2024-07-25

申请号：US18417299

申请日：2024-01-19

Applicant: MABWELL THERAPEUTICS, INC.

Inventor： Yubin WANG ,  Lei HUANG ,  Xin DU

IPC: C07K16/18 ,  A61K39/00 ,  A61P25/28 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61P25/28 ,  G01N33/6857 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/70

Abstract: The present disclosure provides anti-amyloid β (Aβ) antibodies and antibody fragments that preferentially bind soluble amyloid Aβ protofibril/oligomer and trigger ADPC in microglial cells, anti-amyloid β (Aβ) antibodies and antibody fragments that reduce soluble amyloid Aβ protofibril/oligomer levels and insoluble amyloid Aβ plaque in brain tissue, and the use of anti-Aβ protofibril/oligomer antibodies and antibody fragments in therapy, prophylaxis, diagnosis, screening, and monitoring of conditions associated with Aβ protein aggregation, in particular Alzheimer's disease (AD).

公开(公告)号：US20240209081A1

公开(公告)日：2024-06-27

申请号：US18288268

申请日：2021-04-29

Applicant: GENOME AND COMPANY

Inventor： Bu Nam JEON ,  Youn Kyung HOUH ,  Yun Yeon KIM ,  Mi Young CHA

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C12N15/63 ,  G01N33/574 ,  G01N33/68

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K16/2818 ,  C12N15/63 ,  G01N33/574 ,  G01N33/68 ,  A61K2039/505 ,  C07K2317/70 ,  C07K2317/92

Abstract: The present invention relates to anti-CNTN4 antibodies or antigen-binding fragments thereof, and use thereof for activating T cells that upregulate a cell-mediated immune response, for example, use thereof for the treatment of cancer.

公开(公告)号：US20240101669A1

公开(公告)日：2024-03-28

申请号：US18448870

申请日：2023-08-11

Applicant: Compugen Ltd.

Inventor： Mark White ,  Sandeep Kumar ,  Christopher Chan ,  Spencer Liang ,  Lance Stapleton ,  Andrew W. Drake ,  Yosi Gozlan ,  Ilan Vaknin ,  Shirley Sameah-Greenwald ,  Liat Dassa ,  Zohar Tiran ,  Gad S. Cojocaru ,  Leonard Presta ,  Richard Theolis

IPC: C07K16/28 ,  C07K7/06 ,  G01N33/574

CPC classification number: C07K16/2803 ,  C07K7/06 ,  G01N33/57484 ,  C07K2317/33 ,  C07K2317/70 ,  C07K2317/74 ,  C07K2319/30 ,  C07K2319/32 ,  C12N15/1138

Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.

公开(公告)号：US11919959B2

公开(公告)日：2024-03-05

申请号：US16992497

申请日：2020-08-13

Applicant: Cancer Research Technology Limited

Inventor： Roy Bicknell ,  Peter Noy ,  Kabir Ali Khan

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  G01N33/50 ,  A61K39/00

CPC classification number: C07K16/2851 ,  A01K67/0278 ,  A61P35/00 ,  C07K16/30 ,  G01N33/5008 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0375 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/76

Abstract: The invention provides a method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2. The inhibitor may be an antibody, a polypeptide, a peptide, a polynucleotide, a peptidomimetic, a natural product, a carbohydrate, an aptamer or a small molecule.

公开(公告)号：US20230365705A1

公开(公告)日：2023-11-16

申请号：US18028170

申请日：2021-09-28

Applicant: DYNAMICURE BIOTECHNOLOGY LLC

Inventor： Zirong CHEN ,  Roxann GUERRETTE ,  Gregory JONES ,  Shigeru KOMABA ,  Jian LI ,  Angela NORTON ,  Lihua WU ,  Zhinan XIA

IPC: C07K16/28 ,  C12N15/63 ,  A61P35/04

CPC classification number: C07K16/2896 ,  C12N15/63 ,  A61P35/04 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/31

Abstract: The present application provides anti-CD93 constructs that bind to CD93 (e.g., anti-CD93 antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-CD93, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-CD93 construct, pharmaceutical compositions containing the anti-CD93 construct, and methods of using the anti-CD93 construct or compositions.

公开(公告)号：US11795220B2

公开(公告)日：2023-10-24

申请号：US16904510

申请日：2020-06-17

Applicant: Compugen Ltd.

Inventor： Mark White ,  Sandeep Kumar ,  Christopher Chan ,  Spencer Liang ,  Lance Stapleton ,  Andrew W. Drake ,  Yosi Gozlan ,  Ilan Vaknin ,  Shirley Sameah-Greenwald ,  Liat Dassa ,  Zohar Tiran ,  Gad S. Cojocaru ,  Leonard Presta ,  Richard Theolis

IPC: C07K16/28 ,  C07K7/06 ,  G01N33/574 ,  C12N15/113

CPC classification number: C07K16/2803 ,  C07K7/06 ,  G01N33/57484 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C07K2319/32 ,  C12N15/1138 ,  C12N2310/14 ,  G01N2333/47

Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.

公开(公告)号：US11789021B2

公开(公告)日：2023-10-17

申请号：US16067208

申请日：2017-01-02

Applicant: Progastrine et Cancers S.À R.L.

Inventor： Alexandre Prieur

IPC: G01N31/00 ,  G01N33/53 ,  G01N33/574 ,  C07K16/26 ,  C07K16/30

CPC classification number: G01N33/57407 ,  C07K16/26 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/70 ,  C07K2317/73 ,  C07K2317/76 ,  G01N2333/595

Abstract: The present invention relates to methods for the in vitro diagnosis of esophageal cancer, and to compositions and methods for the prevention or the treatment of esophageal cancer. Disclosed are said compositions that include an antibody binding to progastrin and disclosed are methods that include the use of an antibody binding to progastrin.

公开(公告)号：US20230285513A1

公开(公告)日：2023-09-14

申请号：US18064793

申请日：2022-12-12

Applicant: SciClone Pharmaceuticals International Ltd.

Inventor： Robert S. KING ,  Cynthia W. TUTHILL ,  Friedhelm BLOBEL

IPC: A61K38/22 ,  A61K45/06 ,  A61K31/44 ,  A61K31/165 ,  C07K16/28 ,  A61K39/395 ,  A61K31/655 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61P35/00 ,  A61P35/04

CPC classification number: A61K38/2292 ,  A61K45/06 ,  A61K31/44 ,  A61K31/165 ,  C07K16/2818 ,  A61K39/39558 ,  A61K31/655 ,  A61K38/193 ,  A61K38/2046 ,  A61K38/21 ,  A61P35/00 ,  A61P35/04 ,  C07K2317/70

Abstract: The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and/or optionally one or more additional anti-cancer agents.

公开(公告)号：US20230220070A1

公开(公告)日：2023-07-13

申请号：US18056635

申请日：2022-11-17

Applicant: Arialys Therapeutics, Inc.

Inventor： Satoshi KUBO ,  Atsuo KANNO ,  Daisuke YAMAJUKU ,  Takuya KITO ,  Masashi MAEDA ,  Takuma MIHARA

IPC: C07K16/28 ,  C12N15/63 ,  A61P25/00

CPC classification number: C07K16/28 ,  C12N15/63 ,  A61P25/00 ,  C07K2317/565 ,  C07K2317/52 ,  C07K2317/24 ,  C07K2317/70

Abstract: The present invention addresses the problem of providing a novel therapeutic agent for treating patients with anti NMDAR encephalitis. Patients with an anti NMDAR encephalitis have a pathogenic anti-human NR1 antibody that induces internalization of NMDAR on cell surface. As a result, NMDAR function is weakened in the patients' brain. The present inventors found that the one-armed anti-human NR1 antibody according to the present invention binds to NR1 competitively with the pathogenic anti-human NR1 antibody and inhibits the internalization of NMDAR by the pathogenic anti-human NR1 antibody to thereby exhibit therapeutic effect on anti NMDAR encephalitis. Accordingly, the present invention provides the a one-armed anti-human NR1 antibody, a polynucleotide encoding the antibody, an expression vector containing the polynucleotide, a host cell transformed by the expression vector, a method for producing the antibody, a pharmaceutical composition comprising the antibody, a use of the antibody in the manufacture of the pharmaceutical composition, and a method for treating anti NMDAR encephalitis using the antibody.